Drugs / 90Y-IMP288
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02300922 | Jan 2015 → Sep 2017 | colorectal cancer | Nantes University Hospital | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-IMP288 | “This study investigates a pretargeted radioimmunotherapy (pRAIT) with the anti-carcinoembryonic antigen (CEA) TF2 bispecific monoclonal antibody (BsMAb) and the 90Y-IMP288...” NCT02300922 ↗ |
| Modality | Peptide | “90Y-IMP288 radio-labeled peptide” NCT02300922 ↗ |